Journal of Pediatric Biochemistry 2014; 04(01): 023-032
DOI: 10.1055/s-0036-1586458
Review Article
Georg Thieme Verlag KG Stuttgart – New York

Current role of enzyme analysis for urea cycle disorders

Matthias Gautschi
a   Pediatric Endocrinology, Diabetology and Metabolism, University Children's Hospital, Bern, Switzerland
b   University Institute of Clinical Chemistry, Inselspital, Bern, Switzerland
,
Sandra Eggimann
a   Pediatric Endocrinology, Diabetology and Metabolism, University Children's Hospital, Bern, Switzerland
b   University Institute of Clinical Chemistry, Inselspital, Bern, Switzerland
,
Jean-Marc Nuoffer
a   Pediatric Endocrinology, Diabetology and Metabolism, University Children's Hospital, Bern, Switzerland
b   University Institute of Clinical Chemistry, Inselspital, Bern, Switzerland
› Author Affiliations

Subject Editor:
Further Information

Publication History

28 January 2014

28 January 2014

Publication Date:
03 August 2016 (online)

Abstract

Urea cycle disorders (UCD) are due to defects of any of its six enzymes or two transporters. The definitive diagnosis of defects of the three mitochondrial enzymes, N-acetylglutamate synthase (NAGS), carbamylphosphate synthetase I (CPS1) and ornithine transcarbamylase (OTC) depends on either molecular mutation analysis or measurement of enzyme activity, whereas the diagnosis of deficiencies of the three cytosolic enzymes argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL) and arginase I (ARG1) is usually straightforward, based on marker metabolites. Enzyme assays for all UCD have been used since their first description, for disease confirmation and in some instances even for prenatal diagnosis. The genetic bases of the UCD have only been unraveled from the 1980s; the last gene cloned being the NAGS gene in 2002. In this review we discuss the enzymatic assays for all urea cycle enzymes from a historical perspective, their potential and drawbacks, and the current role of enzymatic analysis in UCD in general.